Navigation Links
Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013
Date:5/20/2013

SAN DIEGO, May 20, 2013 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC) a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced it will highlight its efforts to expand research and innovation surrounding its physiology technologies, including its Fractional Flow Reserve (FFR) and iFR® (Instant Wave-Free Ratio™)1 technologies, via various clinical and educational presentations and events at EuroPCR 2013 in Paris.

"Volcano is committed to making clinical and technological advances that expand access to functional management," commented Michele Perrino , president of Europe, Middle East, Africa, and India Operations of Volcano. "Our focus at EuroPCR is to introduce our latest functional management technologies and clinical data, and demonstrate their potential to improve both patient care and the experience for our physician partners in Europe. Given our commitment to provide physicians with choice, we are excited to feature iFR®, our novel hyperemia-free software modality, and our Verrata™ Pressure Guide Wire, which upon regulatory clearance will be our fifth new guide wire in five years."2

Volcano will formally launch its iFR® modality and CORE® Integrated System, and display the Verrata™ Wire at the conference. Volcano will showcase its future and currently available physiology, imaging, and multi-modality systems products in the company's exhibit hall booth #M71.

Featured events for Volcano include four live case symposia demonstrating the benefits of incorporating both FFR and our iFR® modality in simple and complex cases, the presentation of the findings from the Adenosine Vasodilator Independent Stenosis Evaluation II (ADVISE II) study data at a hot line session, and over 10 scientific podium presentations featuring advanced physiology using Volcano products.

Key Events
Wednesday, May 22, 10:50 – 11:30 a.m.
Complex bifurcation stenting: LIVE demonstration of emerging techniques
LIVE iFR® demonstration from Erasmus University Medical Center, Thorax Center – Rotterdam, The Netherlands
Theatre Bleu

Thursday, May 23, 9:45 - 11:45 a.m.
Adenosine Vasodilator Independent Stenosis Evaluation II (ADVISE II)
Hot Line - Evolving procedural strategies
Room 351                        

Thursday, May 23, 4:45 – 6:45 p.m.
Physiological Stenosis Assessment with FFR and Instant Wave-Free Ratio: We Need Both!
Live case demonstrations (simple and multivessel disease) from St. Thomas' Hospital, London, followed by panel discussions
Theatre Bordeaux

Friday, May 24, 9:00 – 12:30 p.m.
Complex cardiovascular interventions and new techniques – Master LIVE demonstrations
Continuous LIVE FFR and iFR® demonstrations from Sunninghill and Sunward Park Hospitals, South Africa and St Thomas' Hospital – London, United Kingdom
Main Arena

Daily, 12:00 – 3:00 p.m.
Meet the iFR® Experts
Booth #M71

About Volcano Corporation
Volcano Corporation is revolutionizing the medical device industry with a broad suite of technologies that make imaging and therapy simpler, more informative and less invasive. Its products empower physicians around the world with a new generation of analytical tools that deliver more meaningful information - using sound and light as the guiding elements. Founded in cardiovascular care and expanding into other specialties, Volcano is changing the assumption about what is possible in improving patient outcomes by combining imaging and therapy together. 

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995.  Any statements in this release that are not historical facts may be considered "forward-looking statements".  Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause Volcano's results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ include the pace and extent of market adoption of the company's products and technologies; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; unexpected manufacturing issues; growth strategies; timing and achievement of product development milestones; outcome of ongoing litigation; the impact and benefits of market development; product introductions; unexpected new data, safety and technical issues; market conditions; and other risks inherent to medical device development and commercialization. These and additional risks and uncertainties are more fully described in Volcano's filings made with the Securities and Exchange Commission, including our recent quarterly report on Form 10-Q. Undue reliance should not be placed on forward-looking statements which speak only as of the date they are made. Volcano undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

1 Our iFR® software modality is approved in CE mark countries.
2 Verrata™ Pressure Guide Wire is 510(k) and CE mark pending, and is not currently commercially available for sale.


'/>"/>
SOURCE Volcano Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Volcano Corporation Presentation At JMP Securities Conference To Be Webcast
2. Volcano to Highlight its Leadership in Precision Guided Therapy at EuroPCR 2012
3. Volcano Corporation Presentation At Jefferies Conference To Be Webcast
4. Volcano Corporation Presentation at Wells Fargo Conference to be Webcast
5. Volcano Corporation Schedules Second Quarter Conference Call, Webcast
6. Volcano Corporation Reports 13 Percent Growth In Second Quarter Revenues; FFR Disposable Revenues Increase 38 Percent
7. Volcano Corporation Presentation At Canaccord Genuity Conference To Be Webcast
8. FAME 2 Published in the New England Journal of Medicine, Volcano participates in the $84M NIH-Sponsored ISCHEMIA Trial
9. Volcano Corporation Presentation At Stifel Nicolaus Conference To Be Webcast
10. Volcano Announces Previous St. Jude Medical Products Infringe Volcano Patent and Jury Verdicts in Patent Trials with St. Jude Medical
11. Volcano Corporation Schedules Third Quarter Conference Call, Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered ... Latin America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the ... in the world, and the most handsome men, look naturally attractive. Plastic surgery ...
Breaking Medicine News(10 mins):